Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

NCT05263492 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Closed early due to low enrollment rates

Conditions

Endometrial Cancer
Mismatch Repair-Proficient
Recurrent Endometrial Cancer

Interventions

DRUG: Lenvatinib
DRUG: Pembrolizumab

Sponsor

Virginia Commonwealth University